Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Oncoimmunology|July 4, 2015
"<i>In situ</i>" vaccination for systemic effects in follicular lymphomaArne Kolstad, Johanna Olweus
Acta Oncologica (Stockholm, Sweden)|August 1, 2017
Use of Alternative Medicine Among Norwegian Cancer Patients is Associated with Mental Distress - A Follow-up StudyTerje Risberg, Arne Kolstad, Barrie R Cassileth
Acta Oncologica (Stockholm, Sweden)|December 4, 2003
Use of alternative medicine among Norwegian cancer patients is associated with mental distress--a follow-up studyTerje Risberg, Arne Kolstad, Barrie R Cassileth
Hematological Oncology|April 11, 2017
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 yearsDlawer Abdulla Barzenje, Arne Kolstad, Waleed Ghanima, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|November 24, 2004
The Patient Experiences Questionnaire: development, validity and reliabilityKjell I Pettersen, Marijke Veenstra, Bjørn Guldvog, et al.
Scandinavian Journal of Psychology|March 12, 2002
Structure of conduct problems in adolescenceElisabet E Storvoll, Lars Wichstrøm, Arne Kolstad, et al.
Acta Oncologica (Stockholm, Sweden)|August 24, 2021
Myelosuppression in patients treated with <sup>177</sup>Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variableJohan Blakkisrud, Ayca Løndalen, Jostein Dahle, et al.
Haematologica|January 19, 2007
Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimenArne Kolstad, Harald Holte, Alexander Fosså, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 18, 2003
[Should alternative therapists treat cancer--what is the opinion of oncology health personnel?]Terje Risberg, Arne Kolstad, Erik A Wist, et al.
Molecular Imaging and Biology|April 29, 2022
FDG PET/CT and Dosimetric Studies of <sup>177</sup>Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?Ayca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, et al.
Pageof 10